Chapter 2: Clinical and Mechanistic Potential of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors in Heart Failure with Preserved Ejection Fraction
Open Access
- 7 May 2023
- journal article
- research article
- Published by Elsevier in The American Journal of Medicine
- Vol. 137 (2) , S9-S24
Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim
This publication has 164 references indexed in Scilit:
- Cardiac Metabolism in Heart FailureCirculation Research, 2013
- A Novel Paradigm for Heart Failure With Preserved Ejection FractionJACC, 2013
- Low Myocardial Protein Kinase G Activity in Heart Failure With Preserved Ejection FractionCirculation, 2012
- Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection FractionCirculation, 2012
- Endothelial Dysfunction in DiabetesDiabetes Care, 2011
- Beneficial Cardiovascular Effects of Bariatric Surgical and Dietary Weight Loss in ObesityJACC, 2009
- Heart Failure With Preserved Ejection Fraction Is Characterized by Dynamic Impairment of Active Relaxation and Contraction of the Left Ventricle on Exercise and Associated With Myocardial Energy DeficiencyJACC, 2009
- The role of exercise and PGC1α in inflammation and chronic diseaseNature, 2008
- Lifetime Risk for Developing Congestive Heart FailureCirculation, 2002
- Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trialsJACC, 1998